PATH vs TLRY
Uipath Inc (PATH) versus Tilray Inc (TLRY) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Tilray Inc (TLRY) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported TLRY revenue for 2025-05-31 was $821.3M. Net income was -$2.18B. Revenue was up 4.1% from 2024-05-31 to 2025-05-31. TLRY currently screens at market cap $573.9M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. TLRY currently screens at market cap $573.9M.
Not investment advice. Open the PATH and TLRY stock pages for the full models.
Not investment advice.